At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INTS Intensity Therapeutics, Inc.
Trading 12-22 13:35:21 EST
0.4200
+0.0096
+2.34%
High0.4278Low0.4060Vol801.84K
Open0.4200D1 Closing0.4104Amplitude5.31%
Mkt Cap25.23MTradable Cap22.58MTotal Shares60.06M
T/O332.27KT/O Rate1.49%Tradable Shares53.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Intensity Therapeutics Inc. Releases Clinical Data on Anthracycline-Free Treatment for Early-Stage Triple Negative Breast Cancer
Reuters  ·  12-18
Intensity Therapeutics Inc. Releases Clinical Data on Anthracycline-Free Treatment for Early-Stage Triple Negative Breast Cancer
Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial
Reuters  ·  12-11
Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
Reuters  ·  12-06
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
Reuters  ·  12-05
BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
BUZZ-Intensity Therapeutics jumps after Nasdaq grants compliance extension
Reuters  ·  12-05
BUZZ-Intensity Therapeutics jumps after Nasdaq grants compliance extension
BRIEF-Intensity Therapeutics Granted 180-Day Extension
Reuters  ·  12-05
BRIEF-Intensity Therapeutics Granted 180-Day Extension
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance With Nasdaq's Minimum Bid Price Requirement
THOMSON REUTERS  ·  12-05
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance With Nasdaq's Minimum Bid Price Requirement
BRIEF-Intensity Therapeutics Files For Offering Of Up To $30 Million Common Stock - SEC Filing
Reuters  ·  12-04
BRIEF-Intensity Therapeutics Files For Offering Of Up To $30 Million Common Stock - SEC Filing
Intensity Therapeutics Unveils New Breast Cancer Therapy Data at 2025 SABCS
Reuters  ·  12-04
Intensity Therapeutics Unveils New Breast Cancer Therapy Data at 2025 SABCS
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
THOMSON REUTERS  ·  12-04
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics Inc - Files for Offering of up to $30 Mln Common Stock - SEC Filing
THOMSON REUTERS  ·  12-04
Intensity Therapeutics Inc - Files for Offering of up to $30 Mln Common Stock - SEC Filing
Analysts Offer Insights on Healthcare Companies: Curis (CRIS) and Intensity Therapeutics, Inc. (INTS)
TIPRANKS  ·  11-13
Analysts Offer Insights on Healthcare Companies: Curis (CRIS) and Intensity Therapeutics, Inc. (INTS)
Intensity Therapeutics Q3 net loss narrows to $2.7 mln
Reuters  ·  11-07
Intensity Therapeutics Q3 net loss narrows to $2.7 mln
Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027
Reuters  ·  11-07
Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027
BRIEF-Intensity Therapeutics Q3 Operating Income USD -2.733 Million
Reuters  ·  11-07
BRIEF-Intensity Therapeutics Q3 Operating Income USD -2.733 Million
Intensity Therapeutics Q3 Basic EPS USD -0.06
THOMSON REUTERS  ·  11-07
Intensity Therapeutics Q3 Basic EPS USD -0.06
Intensity Therapeutics Raises $4 Million in Registered Direct Offering
Reuters  ·  10-31
Intensity Therapeutics Raises $4 Million in Registered Direct Offering
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
THOMSON REUTERS  ·  10-31
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Intensity Therapeutics Inc - Expects Cash Runway Until End of Q1 2027
THOMSON REUTERS  ·  10-31
Intensity Therapeutics Inc - Expects Cash Runway Until End of Q1 2027
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know
Benzinga_recent_news  ·  10-31
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know

Introduction

Company Name.
Intensity Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Issue price:
--